09/18/23 8:00 AMNasdaq : TCON clinical triallow floatTRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipelineRHEA-AIpositive
09/05/23 4:02 PMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals Announces Participation at Upcoming Investor ConferencesTRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with otherRHEA-AIneutral
08/14/23 4:02 PMNasdaq : TCON earningslow floatTRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with otherRHEA-AIneutral
08/02/23 4:05 PMNasdaq : TCON conferencesearningslow floatTRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with otherRHEA-AIneutral
07/11/23 8:00 AMNasdaq : TCON low floatTRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab BiopharmaTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent productRHEA-AIpositive
06/20/23 8:00 AMNasdaq : TCON clinical triallow floatTRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal TrialSingle Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded Independent Central Review Achieved to Date in Single Agent Envafolimab Cohort without any > Grade 2 Drug RelatedRHEA-AIpositive
06/16/23 8:00 AMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual ConferenceTRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platformRHEA-AIneutral
06/15/23 8:00 AMNasdaq : TCON low floatTRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab BiopharmaTRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platformRHEA-AIneutral
06/02/23 8:00 AMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals to Present at the Jefferies Healthcare ConferenceTRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platformRHEA-AIneutral
05/30/23 8:00 AMNasdaq : TCON low floatTRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual MeetingTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIpositive